Brookfield Real Assets Income Fund (RA) Stock
Key stats
- Market cap
- $660.29M
- Volume
- Loading
- 52-week high
- $13.59
- 52-week low
- $11.41
Source: third-party data provider, as of November 13, 2026
Compare with RA
Recent news

LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
RA

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists
NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists
RA

RA: Reiterate Avoid Recommendation
RA: Reiterate Avoid Recommendation
RA

Brookfield Real Assets: 10% Yield And A Large Discount Are Not Enough
Brookfield Real Assets: 10% Yield And A Large Discount Are Not Enough
RA
Technical indicators
- RSI 14
- 54.03
- MACD 12/26/9
- 0.07
- EMA 9 of MACD
- 0.02
- MACD histogram
- 0.05
- SMA 50
- $11.84
- Price above SMA 50
- EMA 50
- $11.93
- Price above EMA 50
- SMA 200
- $12.62
- Price below SMA 200
- EMA 200
- $12.48
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
RA

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists
NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists
RA

RA: Reiterate Avoid Recommendation
RA: Reiterate Avoid Recommendation
RA

Brookfield Real Assets: 10% Yield And A Large Discount Are Not Enough
Brookfield Real Assets: 10% Yield And A Large Discount Are Not Enough
RA

Bonds Are Boring? Not When They Throw Off 10%+ Dividends
Bonds Are Boring? Not When They Throw Off 10%+ Dividends
RA

RA: Discount Continues To Leave Some Opportunity
RA: Discount Continues To Leave Some Opportunity
RA

CEF Weekly Commentary | Swap Some MAIN Bonds?
CEF Weekly Commentary | Swap Some MAIN Bonds?
RA

Brookfield Real Assets Vs SJNK: Birds Of A Feather
Brookfield Real Assets Vs SJNK: Birds Of A Feather
RA

This Monthly-Paying Mini-Portfolio Delivers 11.1% Each Year
This Monthly-Paying Mini-Portfolio Delivers 11.1% Each Year
RA

RA: Big Cut Leads To Opportunity
RA: Big Cut Leads To Opportunity
RA
About Brookfield Real Assets Income Fund
Brookfield Real Assets Income Fund Inc. seeks to provide a high level of total return, primarily through high current income and secondarily, growth of capital. The Fund primarily invests in securities and other instruments of real asset companies and issuers, including, but not limited to, real estate securities, infrastructure securities, and natural resources securities.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Samuel Matthias Diedrich | Portfolio Manager | — |
Fundamentals
Valuation
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.03
- MACD 12/26/9
- 0.07
- EMA 9 of MACD
- 0.02
- MACD histogram
- 0.05
- SMA 50
- $11.84
- Price above SMA 50
- EMA 50
- $11.93
- Price above EMA 50
- SMA 200
- $12.62
- Price below SMA 200
- EMA 200
- $12.48
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.2 | -1.3 | ||||||||||
| 2022 | -1.4 | -2.2 | -0.2 | -1.2 | -2.8 | -7.0 | +9.7 | -4.0 | -9.8 | -2.1 | +2.3 | -9.7 |
| 2023 | +6.1 | +0.7 | -7.7 | +2.4 | -5.4 | +2.2 | +1.4 | -24.4 | -3.2 | +0.3 | +4.5 | +0.9 |
| 2024 | +1.2 | -2.0 | -0.2 | -2.9 | +1.2 | -0.2 | +1.6 | +3.2 | +2.9 | -2.7 | +0.8 | -2.1 |
| 2025 | +0.4 | +0.0 | -1.4 | -1.6 | -0.4 | +3.4 | -1.3 | +2.3 | -1.2 | -2.1 | +0.4 | -1.1 |
| 2026 | +0.6 | +3.0 | -4.5 | +0.8 | -1.7 | +1.3 | -0.5 | -2.2 | -7.7 | +1.5 | +0.8 |



